Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Tsuji, Hideaki; Nakashima, Ran; Hosono, Yuji; Imura, Yoshitaka; Yagita, Masato; Yoshifuji, Hajime; Hirata, Shintaro; Nojima, Takaki; Sugiyama, Eiji; Hatta, Kazuhiro; Taguchi, Yoshio; Katayama, Masaki; Tanizawa, Kiminobu; Handa, Tomohiro; Uozumi, Ryuji; Akizuki, Shuji; Murakami, Kosaku; Hashimoto, Motomu; Tanaka, Masao; Ohmura, Koichiro; Mimori, Tsuneyo

doi:10.1002/art.41105

Public

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Published in Arthritis & Rheumatology • Sep 16, 2019

Authors:

Hideaki Tsuji

Ran Nakashima

Yuji Hosono

Abstract

OBJECTIVE: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation-associated gene 5 (anti-MDA-5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor prognosis. Because there is no established treatment, we undertook this study to prospectively ev...

Subject

Medicine

Regimen

Cyclophosphamide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!